86 related articles for article (PubMed ID: 3971392)
21. Phase II trial of bisantrene in patients with metastatic melanoma.
Mackel C; Meyskens FL; Alberts DS
Cancer Treat Rep; 1986 Aug; 70(8):1037-8. PubMed ID: 3731151
[No Abstract] [Full Text] [Related]
22. A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
Herbst RS; Hammond LA; Carbone DP; Tran HT; Holroyd KJ; Desai A; Williams JI; Bekele BN; Hait H; Allgood V; Solomon S; Schiller JH
Clin Cancer Res; 2003 Sep; 9(11):4108-15. PubMed ID: 14519633
[TBL] [Abstract][Full Text] [Related]
23. Phase II trial of paclitaxel by 96-hour continuous infusion in combination with cisplatin for patients with advanced non-small cell lung cancer.
Breathnach OS; Georgiadis MS; Schuler BS; Pizzella P; Llorens V; Kasturi V; Steinberg SM; O'Neil K; Takimoto CH; Johnson BE
Clin Cancer Res; 2000 Jul; 6(7):2670-6. PubMed ID: 10914708
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.
Schiller JH; Larson T; Ou SH; Limentani S; Sandler A; Vokes E; Kim S; Liau K; Bycott P; Olszanski AJ; von Pawel J
J Clin Oncol; 2009 Aug; 27(23):3836-41. PubMed ID: 19597027
[TBL] [Abstract][Full Text] [Related]
25. Paclitaxel, carboplatin, and vinorelbine in the treatment of advanced non-small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Burris HA; Morrissey LH; Thomas M; Erland JB; Butts JA; Joseph G; Kalman L; Greco FA
Cancer J; 2000; 6(3):151-6. PubMed ID: 10882330
[TBL] [Abstract][Full Text] [Related]
26. A phase II study of recombinant human interleukin-4 for advanced or recurrent non-small cell lung cancer.
Vokes EE; Figlin R; Hochster H; Lotze M; Rybak ME
Cancer J Sci Am; 1998; 4(1):46-51. PubMed ID: 9467046
[TBL] [Abstract][Full Text] [Related]
27. Sequential chemoradiation therapy with vinorelbine, ifosfamide, and cisplatin in stage IIIB non-small cell lung cancer: a phase II study.
Baldini E; Silvano G; Tibaldi C; Campoccia S; Cionini L; Conte P
Semin Oncol; 2000 Feb; 27(1 Suppl 1):28-32. PubMed ID: 10697041
[TBL] [Abstract][Full Text] [Related]
28. Phase II evaluation of aclarubicin in lung cancer: a Southeastern Cancer Study Group Trial.
Kramer BS; Birch R; Gockerman JP; Greco A; Prestridge K
Cancer Treat Rep; 1986 Jun; 70(6):803-4. PubMed ID: 3015404
[No Abstract] [Full Text] [Related]
29. A phase II study of induction chemotherapy followed by concurrent chemoradiotherapy in elderly patients with locally advanced non-small-cell lung cancer.
Giorgio CG; Pappalardo A; Russo A; Santini D; Di Rosa C; Di Salvo C; Castorina S; Marletta F; Bellissima G; Palermo N; Scuderi C; Bordonaro R
Anticancer Drugs; 2007 Jul; 18(6):713-9. PubMed ID: 17762402
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetic re-evaluation and phase I study of high dose epirubicin in advanced non-small cell lung cancer.
Nishio M; Ohata M; Kobayashi H; Suruda T; Uetani K; Funasako M; Nishio K; Sasaki Y; Saijo N
Jpn J Clin Oncol; 1993 Oct; 23(5):284-90. PubMed ID: 8230753
[TBL] [Abstract][Full Text] [Related]
31. Topotecan plus ifosfamide in patients with platinum refractory advanced/metastatic non-small cell lung cancer: a phase II trial.
Lorusso V; Gebbia V; Spada M; Guida M; Cassano G; Brunetti C; Germano D; Nettis G; Izzi G; Galetta D; Giampaglia M; Silvestris N; Colucci G
Oncol Rep; 2005 Dec; 14(6):1547-51. PubMed ID: 16273254
[TBL] [Abstract][Full Text] [Related]
32. [Polychemotherapy of small-cell bronchopulmonary cancer. The advantages of adding the selective cytostatic Riaval].
Păunescu E; Dănălache-Dumitrescu M; Oprişiu G; Smărăndache M; Stoinescu M; Vasile DI; Zaharescu C; Burnea D; Claiciu I; Ghinescu V
Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Pneumoftiziol; 1986; 35(3):233-42. PubMed ID: 3027860
[No Abstract] [Full Text] [Related]
33. Phase II evaluation of pyrazofurin in patients with carcinoma of the lung.
Gralla RJ; Currie VE; Wittes RE; Golbey RB; Young CW
Cancer Treat Rep; 1978 Mar; 62(3):451-2. PubMed ID: 348315
[No Abstract] [Full Text] [Related]
34. Phase II trial of bisantrene in patients with intermediate and high grade diffuse non-Hodgkin's lymphomas.
Miller TP; Jones SE; Alberts DS; Mackel C
Invest New Drugs; 1984; 2(1):75-7. PubMed ID: 6469502
[TBL] [Abstract][Full Text] [Related]
35. Phase II evaluation of bisantrene hydrochloride in refractory malignant melanoma. A Southwest Oncology Group Study.
Alberts DS; Mason-Liddil N; Green SJ; Cowan JD; Fletcher WS; Neilan B; Guy JT; Epstein RB
Invest New Drugs; 1987; 5(3):289-92. PubMed ID: 3667164
[TBL] [Abstract][Full Text] [Related]
36. Phase II trial of Bisantrene for metastatic melanoma: an Illinois cancer council study.
Stiff PJ; Sweet D; Kilton LJ; Johnson CM; Muntean B; Blough RR
Med Pediatr Oncol; 1991; 19(2):126-8. PubMed ID: 2011097
[TBL] [Abstract][Full Text] [Related]
37. Experimental studies and phase II trial of bisantrene in advanced urothelial malignancies.
Scher HI; Ahmed T; Yagoda A; Kyriazis AP; Watson RC
Cancer Invest; 1985; 3(2):123-7. PubMed ID: 3995377
[TBL] [Abstract][Full Text] [Related]
38. Phase II studies of PCNU and bisantrene in advanced renal cell carcinoma.
Elson PJ; Earhart RH; Kvols LK; Spiegel R; Keller AM; Kies MS; Davis TE; Stevens C; Gumas L; Trump DL
Cancer Treat Rep; 1987 Mar; 71(3):331-2. PubMed ID: 3815401
[No Abstract] [Full Text] [Related]
39. Phase II trial of bisantrene in hepatocellular carcinoma: a Southwest Oncology Group Study.
Brown TD; Fleming TR; Shildt RA; Cowan JD
Cancer Treat Rep; 1987 Nov; 71(11):1101-2. PubMed ID: 2824048
[No Abstract] [Full Text] [Related]
40. Phase II evaluation of bisantrene in acute leukemia. A Southwest Oncology Group Study.
Mills GM; Dahlberg S; Cowan J; Neilan BA; Gumbart CH; Hussein K; Coltman CA
Am J Clin Oncol; 1989 Dec; 12(6):507-10. PubMed ID: 2589232
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
